AXDX - Accelerate Diagnostics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Accelerate Diagnostics, Inc.

3950 South Country Club Road
Suite 470
Tucson, AZ 85714
United States

IndustryMedical Laboratories & Research
Full Time Employees193

Key Executives

Mr. Lawrence MehrenChief Exec. Officer, Pres and Director360.58kN/A52
Mr. Steve ReichlingChief Financial Officer, Chief Accounting Officer and Sec.230.38kN/A40
Mr. Kurt ReinhardtHead of OperationsN/AN/AN/A
Dr. Romney M. Humphries Ph.D., D(ABMM), M (ASCP)CMChief Scientific OfficerN/AN/AN/A
Mr. Steven W. MetzgerHead of Discovery & New ProductsN/AN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Corporate Governance

Accelerate Diagnostics, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.